Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.005 per share
-
Shares outstanding
-
110,002,045
-
Total 13F shares
-
331,434
-
Share change
-
-1,816
-
Total reported value
-
$728,396
-
Price per share
-
$2.18
-
Number of holders
-
19
-
Value change
-
-$4,855
-
Number of buys
-
5
-
Number of sells
-
7
Institutional Holders of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) as of Q3 2023
As of 30 Sep 2023,
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
331,434 shares.
The largest 10 holders included
Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, Corient Private Wealth LLC, Sippican Capital Advisors, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., BALDWIN BROTHERS LLC/MA, Tower Research Capital LLC (TRC), and UBS Group AG.
This page lists
20
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.